Multidisciplinary treatment of synchronous primary rectal and prostate cancers.
BACKGROUND
A 58-year-old Caucasian man with a history of irritable bowel syndrome and occasional rectal bleeding presented with a 4-week history of progressive, bright red blood per rectum. A digital rectal examination revealed a 3 cm distal, midrectal mass. Laboratory tests showed an elevated serum prostate-specific antigen of 32 ng/ml but other physical and medical examinations were unremarkable.


METHODS
Digital rectal examination, colonoscopy, rectal mass biopsy, endorectal ultrasound, transrectal ultrasound-guided prostate biopsy, CT scan and MRI.


METHODS
Clinical stage III (T3N1M0), moderately differentiated adenocarcinoma of the rectum and clinical stage II (T1cN0M0) adenocarcinoma of the prostate.


RESULTS
Intensity-modulated radiation therapy, chemoradiation, chemotherapy, hormone therapy and surgery.
Colonias
Athanasios
A
Allegheny General Hospital Department of Radiation Oncology, Pittsburgh, PA 15212, USA. acolonia@wpahs.org
Farinash
Lloyd
L
Miller
Linda
L
Jones
Sandra
S
Medich
David S
DS
Greenberg
Larisa
L
Miller
Ralph
R
Parda
David S
DS
D000230:Adenocarcinoma / Q000473:pathology* / Q000628:therapy; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000473:pathology* / Q000628:therapy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy; D012004:Rectal Neoplasms / Q000473:pathology* / Q000628:therapy
D018931:Antineoplastic Agents, Hormonal